Kornimate/medical-research-clean huggingface dataset:
quality of life changes on lower extremity lymphedema patients using an advanced pneumatic compression device (pcd)

Conditions: Lymphedema

Summary: assessment of quality of life and symptoms changes in primary or secondary, unilateral or bilateral lower extremity lymphedema patients using an advanced pneumatic compression system.

post-market, on label, multi-center, single arm, observational clinical trial of a prospective cohort of 300 subjects with primary or secondary, unilateral or bilateral, lower extremity lymphedema in the united states. all subjects will receive pneumatic compression treatment for 52 weeks.

Eligibility criteria:
inclusion criteria: * age 18 or older * diagnosis of primary or secondary, unilateral or bilateral, lower extremity lymphedema * ability and willingness to participate in all aspects of the study including following prescribed care * ability to provide informed consent * must have a prescription for the flexitouch (flexitouch system or flexitouch plus) exclusion criteria: * diagnosis of active or recurrent cancer, or less than 3 months at the time of initial evaluation from the completion of chemotherapy, radiation therapy or primary surgery for the treatment of cancer. * active skin or limb infection/inflammatory disease (acute cellulitis, or other uncontrolled skin or untreated inflammatory skin disease) * acute thrombophlebitis (in last 2 months) * pulmonary embolism within the previous 6 months * deep vein thrombosis (dvt) within the previous 3 months * severe peripheral artery disease (critical limb ischemia including ischemic rest pain, arterial wounds, or gangrene) * pulmonary edema * heart failure (acute pulmonary edema, decompensated acute heart failure) * patients with poorly controlled asthma * previous use of the study pneumatic compression device (pcd) * currently using multi-layer bandaging (mlb) unless bandages can be removed for limb circumference measurements * pregnant women or women of childbearing potential not on contraception * any condition where increased venous and lymphatic return is undesirable * currently participating in another medical device or drug clinical trial * signs of noncompliance at the week 4 visit including: using the device less than 3 times per week and/or not attending the scheduled visit.

Keywords: chronic swelling leg lymphedema primary lymphedema secondary lymphedema
the beneficial study: evaluating the efficacy and safety of alagebrium (alt-711) in patients with chronic heart failure

Conditions: Heart Failure

Summary: several lines of evidence have suggested that advanced glycation end-products (ages) play a role in the development and progression of heart failure. the age-crosslink breaker alagebrium (alt-711) improved cardiac function and symptoms in experimental and small human heart failure studies. these results have not yet been confirmed in a randomized controlled clinical trial.

this study is a double-blind, randomized, placebo-controlled, parallel design trial enrolling 100 patients (2x50) with stable chf. patients will be randomized to either 200 mg alagebrium twice daily or placebo for a period of 9 months. efficacy measurements will be performed at baseline, and at the end of the study, and include aerobic capacity (vo2max) exercise testing, echocardiography, minnesota living with heart failure score, ages measurements in blood and skin, nyha heart failure class, patient's and physician's global assessment, and levels of nt-pro-bnp. safety visits are performed at 3 months intervals. in addition, one safety visit will be performed 2 weeks after the randomization visit and 1 month after the last treatment visit. a total of 8 visits will be performed during the entire study.

Eligibility criteria:
inclusion criteria: * nyha ii-iv heart failure * echocardiographic ejection fraction ≤ 40% * duration of heart failure \> 3 months * stable heart failure medical therapy for \> 1 months exclusion criteria: * history of myocardial infarction in previous 6 months * history of stroke in previous 6 months * clinically significant renal, liver, pulmonary,or hematological disease * active and or treated malignancies within 12 months * uncontrolled diabetes mellitus

Keywords: advanced glycation end-products (ages) alegebrium
from acute to chronic postoperative shoulder pain in patients for elective lobectomy

Conditions: Pain

Summary: shoulder pain is a well known problem after thoracical surgery. the pathogenesis of the pain is uncertain, but mainly a mix of referred pain and mechanical strain to the shoulder. it is believed to last a few days. persisting shoulder pain after thoracical surgery is a problem 1 year after surgery, but it is unknown if it is related to acute postoperative shoulder pain. the purpose of the study is to systematically describe postoperative shoulder pain after lobectomy and examine the time progress up to 1 year after surgery.

further study details are provided by departement v, odense university hospital

Eligibility criteria:
inclusion criteria: * patients for elective lobectomy * 18 years or older at the day of the operation * satisfactory abilities to speak and read danish exclusion criteria: * previous thoracical surgery. * patients with diseases in the nervous system. * patients with preoperative shoulder pain, neuropathies or sensory disturbances in the arm or shoulder. * patients who are reoperated in the thorax in the study period or any other body-region within the first 4 postoperative days.

Keywords: postoperative shoulder pain persisting postoperative pain
pneumatic retinopexy for severe bullous retinal detachment

Conditions: Retina Detachment

Summary: to compare the efficacy and safety outcomes of scleral buckling (sb) and drainage-injection-pneumoretinopexy (dip), a modified pneumatic retinopexy technique, in which, before injecting the gas, the drainage of the subretinal fluid is performed with a simultaneous injection of balanced salt solution (bss) in the vitreous chamber, for the treatment of severe superior bullous rhegmatogenous retinal detachment (sbrd).


Eligibility criteria:
inclusion criteria: * provision of written informed consent; * phakic patients aged \< 60 years with no or minimal media opacity; * single or multiple retinal breaks (within 1 clock hour) between 8 to 4 o'clock hours; * patients' capability to maintain suggested head positioning for 5 days after the procedure. exclusion criteria: * retinal detachment with poor subretinal fluid (absence of severe sbrd); * holes, lattice degeneration or traction within the inferior 4 clock hours; * posterior retinal break, situated behind the equator, not suitable for cryotherapy; * any sign of pvr or severe glaucoma; * myopia above 10 diopters.
study on the efficacy and tolerance of a new anti-regurgitation infant formula (stellar)

Conditions: Gastroesophageal Reflux in Children

Summary: the aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.

the study duration is 1 month and 2 days. it is possible to add 2 additional months (optional). the 2 first days (from d-3 to d0) correspond to the pre-selection period. these 2 days are followed by the follow-up month (from d0 to d30). it is possible to add an optional follow up of 2 months (form d30 to d90).

Eligibility criteria:
inclusion criteria: * ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation episodes per day in average during the last 2 days, * exclusive or predominant formula feeding * whose parents signed informed consent exclusion criteria: * preterm infants or birthweight \<2500g * post enteritis lactose intolerance * suspected or diagnosed cow's milk protein allergy requiring an eviction diet * use of medications that may interfere with regurgitation or gastrointestinal transit (such as alginates, laxatives, antibiotics...). all these medications have to be stopped at least 7 days before inclusion visit (v1) * infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject

Keywords: reflux
multidimensional evaluation of daily living activities and quality of life in lung cancer patients

Conditions: Lung Cancer

Summary: the aim of our study was to compare the daily living activities with a performance-based protocol in lung cancer patients and healthy controls.

lung cancer is the abnormal proliferation of cells in the lung tissue and a mass in the lung. the primary symptoms of this health problem include cough, dyspnea, chest pain, hemoptysis and sputum. in addition to these symptoms, muscle strength, respiratory function and effort level are decreased. inadequate daily living activities in cancer patients are expressed.but studies evaluating the activities of daily living in patients with lung cancer are inadequate and patients are evaluated only using scales. for the measurement of functional status in daily living activities, these scales provide important information about the detection of symptoms and the progression of the disease. however, it is very difficult to determine the limitation of perceived difficulty in daily living activities with these scales. in addition, since these scales are a method of measurement, the objectivity is open to discussion. it is thought that a performance-based protocol will facilitate the detection of limitations and provide more objective findings. we think that the londrina protocol fully reflects the activities of daily living and thus will give us an objective measurement. this study will show us the problem and its cause in daily life activities in patients with lung cancer.

Eligibility criteria:
inclusion criteria: * to have a diagnosis of lung cancer * complete chemotherapy * complete radiotherapy * coopere, * accepts participation in the study will be included in the study exclusion criteria: * neurological, cognitive or orthopedic diseases that affect the measurements * acute infection * individuals with other chronic diseases that may affect their walking will not be included in the study
neurological fate, prematurity and genetic susceptibility factors

Conditions: Polymorphism, Restriction Fragment Length; Premature; Infertility of Cervical Origin

Summary: this study could help identify aggravating or protective genetic polymorphisms associated with cerebral palsy. populations of premature babies at different risk of cerebral palsy could thus be individualized with an impact on their monitoring and on the pathophysiological understanding of the processes leading to neurological lesions.


Eligibility criteria:
inclusion criteria: * children born prematurely at term \<34 weeks between 2008 and 2015 * assessed at the age of 2 within the growing together network in pays de loire * parental consent for the collection of data from their child and for intraoral sampling for the search for genetic factors. exclusion criteria: * children who died after the age of 2 * children who refused and / or whose parents refused to participate in the study
vitamin c to decrease effects of smoking in pregnancy on infant lung function (vcsip) longer term follow up

Conditions: Asthma; Pulmonary Function; Wheezing; In Utero Nicotine

Summary: the overall aims of this protocol are to determine whether prenatal supplementation with vitamin c to pregnant smokers can improve pulmonary function at 10 years of age in their offspring. this is an additional continuation of the vitamin c to decrease effects of smoking in pregnancy on infant lung function (vcsip) trial, to follow the offspring through 10 years of age. the hypothesis for this protocol is an extension of the vcsip trial that supplemental vitamin c in pregnant smokers can significantly improve their children's airway function tests. the investigators aim to demonstrate sustained improvement in airway/pulmonary function and trajectory through 10 years of age.

the primary outcome of this longitudinal follow-up study is the comparison of airway function tests (specifically the forced expiratory flow between 25%and 75% of expired volume \[fef25-75\]) measured yearly through 10 years of age by forced expiratory maneuvers with spirometry between the children of the pregnant smokers randomized to vitamin c (500 mg/day) versus placebo during pregnancy. the occurrence of wheeze obtained with quarterly standardized respiratory questionnaires will also be compared between the two groups of children. this is a follow-up of the original "vitamin c to decrease effects of smoking in pregnancy on infant lung function" (vcsip) trial. the secondary outcomes are: 1. a single low dose high-resolution computed tomography (hrct) image of the lungs (acquired during inspiration) will be done at 10 years of age in offspring of pregnant smokers who were randomized to vitamin c (500 mg/day) versus placebo during pregnancy. image analysis will be performed by dr. miranda kirby's quantitative image analysis in medicine laboratory at ryerson university in toronto, on using certified pulmonary image analysis software. the airway lumen cross sectional areas to at least the fifth generation of airways will be compared between the two groups of children. the number of airways and the lumen, wall, and total cross sectional areas and the segment lengths will also be quantified. 2. a secondary aim is to quantify the differences in dna methylation between the two groups and measure the correlation between the differences in dna methylation and respiratory outcomes.

Eligibility criteria:
inclusion criteria: * women and their offspring randomized to vitamin c versus placebo during pregnancy as well as pregnant nonsmokers and their offspring enrolled as the reference group in the original vcsip study exclusion criteria: * participants who specifically withdraw consent

Keywords: asthma pulmonary function pulmonary function testing wheeze vitamin c antioxidants forced expiratory flows spirometry lung function epigenetics high resolution ct scans
chewing and swallowing training program in coffin-lowry syndrome

Conditions: Swallowing Disorder; Chewing Problem

Summary: this study will report the chewing and swallowing disorders of a coffin-lowry syndrome (cls) patient, and effects of chewing and swallowing training on chewing and swallowing function.

patients with cls suffer from spinal deformities, nonconvulsive status epilepticus, obstructive sleeep apnea syndrome, pneumonia, stimulus-induced myoclonus, cases of falls, mechanical ventilation, restrictive lung disease. it was also reported that patients with cls had problems with eating and feeding functions. however there is no study investigating chewing and swallowing functions of this patient population. therefore, the investigators have three main purposes: 1. to chewing and swallowing function in a boy with cls diagnosis who was referred due to coughing during eating, long-lasting wheezing, sputum and inability to intake solid food 2. to investigate the effects of two months of chewing and swallowing training program 3. to present long term follow-up effects on chewing and swallowing function.

Eligibility criteria:
inclusion criteria: * having a diagnosis of cls * having a history of coughing during eating, long-lasting wheezing, sputum * inability to intake solid food. exclusion criteria: - no history of coughing during eating, long-lasting wheezing, sputum
innovative orthosis in hyperkyphosis

Conditions: Postural Kyphosis; Hyperkyphosis

Summary: thoracic hyperkyphosis is a common postural deformity; however, the optimal treatment strategy has yet to be clearly defined. this randomized controlled trial aimed to assess the effectiveness of an innovative three-dimensional printed cover spine orthosis (cso) in managing thoracic hyperkyphosis. specifically, the study compared the effects of the cso on kyphosis angle, quality of life (qol), and user satisfaction with those of a semi-rigid thoracolumbar orthosis (srtlo) that has established efficacy in the literature.

postural kyphosis is associated with various clinical symptoms, including fatigue, pain, weakness of the back extensor muscles, depressive mood, and a reduction in quality of life (qol). previous research has consistently shown that spinal deformities negatively impact overall health, particularly diminishing individuals' qol. although conservative approaches are commonly recommended for managing postural kyphosis, a universally accepted treatment protocol has not yet been established. current evidence suggests that interventions such as exercise, kinesio-taping, and orthotic use may be effective in decreasing the thoracic kyphosis angle (tka). among these, orthotic interventions have been widely employed to correct posture and reduce tka. while various orthosis designs have been studied, and some have demonstrated significant outcomes, there is still no consensus on the most effective orthotic treatment. in light of existing literature and advancements in biomechanics and design technologies, a novel three-dimensional (3d) orthosis was developed to address these gaps. this study aimed primarily to assess the effectiveness of a custom-designed, 3d-printed cover spine orthosis (cso) in reducing tka in individuals with postural kyphosis, in comparison to a semi-rigid thoracolumbar orthosis (srtlo) previously validated in the literature. a secondary objective was to evaluate and compare the effects of both orthoses on quality of life and user satisfaction

Eligibility criteria:
inclusion criteria: * individuals of both sexes (male and female) * aged between 20 and 60 years * presence of thoracic kyphosis angle (tka) ≥ 40° exclusion criteria: * history of spinal surgery or traumatic injury * received physiotherapy treatment within the last six months * diagnosed with congenital spinal deformities or scoliosis * presence of acute musculoskeletal injury * inability to tolerate or adapt to orthotic application

Keywords: thoracic hyperkyphosis postural kyphosis three-dimensional orthosis thoracic kyphosis angle
acute myocardial infarction in native versus non-native young population in saudi arabia

Conditions: Acute Myocardial Infarction

Summary: a retrospective study collecting the data of young patients admitted with diagnosis of acute myocardial infarction.

a retrospective study investigating young adults aged \<45 years for males and \<55 years for females admitted at saud al babtain cardiac center with diagnosis of acute myocardial infarction, determining its risk factors for coronary artery disease (cad) related to cultural characteristics and common positive consanguinity of parents as well as the prevalent diabetes and smoking.

Eligibility criteria:
inclusion criteria: * \<45 years old for male and \<55 years old for female * patients admitted with diagnosis of acute myocardial infarction exclusion criteria: * \ 55 years old male and female * patients admitted with diagnosis other than acute myocardial infarction.

Keywords: young saudi
effect of nurse-assessed remote ischemic preconditioning on improving exercise capacity, endothelial function, and arterial stiffness in patients with heart failure with preserved ejection fraction

Conditions: HF - Heart Failure

Summary: the piric-fep study will be a randomized clinical trial in sedentary patients with heart failure and stable preserved ejection fraction. objectives: 1) to evaluate the efficacy of remote ischemic preconditioning performed by nurses, a noninvasive cardioprotective intervention that uses cycles of ischemia and reperfusion in the extremities, in improving exercise capacity, cardiac function, endothelial function and arterial stiffness, and 2) to analyze its impact on quality of life and its cost-effectiveness compared to conventional treatment. methodology: patients will be recruited in health centers in the city. those assigned to the intervention group will wear a self-administered blood pressure cuff, inflated to 220 mmhg for 5 minutes, followed by 5 minutes of deflation, in repeated cycles four times, five days a week for three months. the control group will receive standard counseling. all participants will be examined, at baseline and at three months. adherence will be defined as completing at least 70% of the sessions. different parameters will be evaluated, including sociodemographic variables, patient's medical history, echocardiography, cardiopulmonary exercise test, endothelial function, arterial stiffness, quality of life, spirometry, blood tests, among others. the study will be approved by an ethics committee, participants will be informed and will have to sign a written consent. the statistical analysis will include three phases: verification of randomization, use of covariance models for dependent variables, and sensitivity analysis with propensity score matching. all analyses will be performed on an intention-to-treat basis.


Eligibility criteria:
inclusion criteria: 1. hf-pef (diagnosis according to the esc 2021 criteria) 1. signs and symptoms of hf 2. a left ventricular ejection fraction ≥50%. 3. objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of left ventricular diastolic dysfunction/elevated left ventricular filling pressures, including elevated natriuretic peptides 2. sedentary men and women (structured exercise \<2 x 30 min/week). 3. age ≥40 years 4. written informed consent 5. clinically stable for 6 weeks 6. optimal medical treatment for ≥6 weeks. exclusion criteria: 1. non-cardiac causes of hf symptoms: * significant valvular or coronary artery disease * uncontrolled hypertension or arrhythmias * primary cardiomyopathies 2. significant pulmonary disease (fev1\<50% predicted, gold iii-iv) 3. inability to exercise or conditions that may interfere with exercise intervention. 4. myocardial infarction within the last 3 months. 5. patients with diabetes and/or peripheral vascular disease. 6. signs of ischemia during maximal cardiopulmonary stress test. 7. comorbidity that may influence prognosis at one year. 8. participation in another clinical trial